F2-isoprostanes as an indicator and risk factor for coronary heart disease

Free Radical Biology and Medicine

Volumn 50, Issue 5, 2011, Pages 559-566

  Davies, Sean S ^a   Roberts II, L Jackson ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Antioxidants; Atherosclerosis; Biomarkers; Cardiovascular disease; Coronary heart disease; Free radicals; Isoprostanes; Lipid peroxidation; Oxidative stress; Polyunsaturated fatty acids

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA TOCOPHEROL; ATORVASTATIN; C REACTIVE PROTEIN; CANDESARTAN; CITRIC ACID; EDETIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYUNSATURATED FATTY ACID; PRAVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ASTHMA; BLOOD SAMPLING; BODY MASS; CALORIC RESTRICTION; CENTRIFUGATION; CHOLESTEROL BLOOD LEVEL; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FREEZE THAWING; GASTRECTOMY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMOLYSIS; HIGH FIBER DIET; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VIVO STUDY; ISCHEMIC HEART DISEASE; ISOTOPE DILUTION ASSAY; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SMOKING; SMOKING CESSATION; SOLID PHASE EXTRACTION; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; WEIGHT REDUCTION; ATHEROSCLEROSIS; BLOOD; CORONARY ARTERY DISEASE;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CORONARY DISEASE; F2-ISOPROSTANES; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS; RISK FACTORS;

EID: 79551488948     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.11.023     Document Type: Review

References (89)

1. M.S. Brown, and J.L. Goldstein Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man Science 185 1974 61 63
2. J.L. Goldstein, Y.K. Ho, S.K. Basu, and M.S. Brown Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition Proc. Natl Acad. Sci. USA 76 1979 333 337
3. M.T. Quinn, S. Parthasarathy, L.G. Fong, and D. Steinberg Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis Proc. Natl Acad. Sci. USA 84 1987 2995 2998
4. S. Parthasarathy, L.G. Fong, D. Otero, and D. Steinberg Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor Proc. Natl Acad. Sci. USA 84 1987 537 540
5. G. Jurgens, H.F. Hoff, G.M. III Chisolm, and H. Esterbauer Modification of human serum low density lipoprotein by oxidation-characterization and pathophysiological implications Chem. Phys. Lipids 45 1987 315 336
6. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts II A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl Acad. Sci. USA 87 1990 9383 9387
7. 4 poisoning? Free Radic. Biol. Med. 38 2005 698 710
8. D.M. Stafforini, J.R. Sheller, T.S. Blackwell, A. Sapirstein, F.E. Yull, T.M. McIntyre, J.V. Bonventre, S.M. Prescott, and L.J. Roberts II Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases J. Biol. Chem. 281 2006 4616 4623
9. J.A. Awad, J.D. Morrow, K. Takahashi, and L.J. Roberts II Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma J. Biol. Chem. 268 1993 4161 4169
10. Z. Wang, G. Ciabattoni, C. Créminon, J. Lawson, G.A. Fitzgerald, C. Patrono, and J. Maclouf Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man J. Pharmacol. Exp. Ther. 275 1995 94 100
11. L.J. Roberts II, K.P. Moore, W.E. Zackert, J.A. Oates, and J.D. Morrow Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans J. Biol. Chem. 271 1996 20617 20620
12. E. Granström, and H. Kindahl Quality control of antibodies with special reference to prostaglandins J. Pharm. Biomed. Anal. 5 1987 759 765
13. S. Devaraj, S.V. Hirany, R.F. Burk, and I. Jialal Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes Clin. Chem. 47 2001 1974 1979
14. D.M. Sasaki, Y. Yuan, K. Gikas, K. Kanai, D. Taber, J.D. Morrow, L.J. Roberts II, and D.M. Callewaert Enzyme immunoassays for 15-F2T isoprostane-M, an urinary biomarker for oxidant stress Adv. Exp. Med. Biol. 507 2002 537 541
15. J. Proudfoot, A. Barden, T.A. Mori, V. Burke, K.D. Croft, L.J. Beilin, and I.B. Puddey Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-a comparison of enzyme immunoassay with gas chromatography/mass spectrometry Anal. Biochem. 272 1999 209 215
16. J. Bessard, J.L. Cracowski, F. Stanke-Labesque, and G. Bessard Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry: comparison with enzyme immunoassay J. Chromatogr. B Biomed. Sci. Appl. 754 2001 333 343
17. D. Ilyasova, J.D. Morrow, A. Ivanova, and L.E. Wagenknecht Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2, 3-dinor-5, 6-dihydro-15-F2t-isoprostane Ann. Epidemiol. 14 2004 793 797
18. C. Soffler, V.L. Campbell, and D.M. Hassel Measurement of urinary F2-isoprostanes as markers of in vivo lipid peroxidation: a comparison of enzyme immunoassays with gas chromatography-mass spectrometry in domestic animal species J. Vet. Diagn. Investig. 22 2010 200 209
19. J.D. Morrow, B. Frei, A.W. Longmire, J.M. Gaziano, S.M. Lynch, Y. Shyr, W.E. Strauss, J.A. Oates, and L.J. Roberts II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage N. Engl. J. Med. 332 1995 1198 1203
20. A. Bachi, E. Zuccato, M. Baraldi, R. Fanelli, and C. Chiabrando Measurement of urinary 8-epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry: basal levels in smokers and nonsmokers Free Radic. Biol. Med. 20 1996 619 624
21. M. Reilly, N. Delanty, J.A. Lawson, and G.A. FitzGerald Modulation of oxidant stress in vivo in chronic cigarette smokers Circulation 94 1996 19 25
22. R. Obwegeser, A. Oguogho, M. Ulm, P. Berghammer, and H. Sinzinger Maternal cigarette smoking increases F2-isoprostanes and reduces prostacyclin and nitric oxide in umbilical vessels Prostaglandins Other Lipid Mediat. 57 1999 269 279
23. P. Montuschi, J.V. Collins, G. Ciabattoni, N. Lazzeri, M. Corradi, S.A. Kharitonov, and P.J. Barnes Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers Am. J. Respir. Crit. Care Med. 162 2000 1175 1177
24. G. Davi, P. Alessandrini, A. Mezzetti, G. Minotti, T. Bucciarelli, F. Costantini, F. Cipollone, G.B. Bon, G. Ciabattoni, and C. Patrono In vivo formation of 8-epi-prostaglandin F2 alpha is increased in hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 17 1997 3230 3235
25. M.P. Reilly, D. Pratico, N. Delanty, G. DiMinno, E. Tremoli, D. Rader, S. Kapoor, J. Rokach, J. Lawson, and G.A. FitzGerald Increased formation of distinct F2 isoprostanes in hypercholesterolemia Circulation 98 1998 2822 2828
26. H. Li, J.A. Lawson, M. Reilly, M. Adiyaman, S.-W. Hwang, J. Rokach, and G.A. FitzGerald Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine Proc. Natl Acad. Sci. USA 96 1999 13381 13386
27. T.M. Lee, T.F. Chou, and C.H. Tsai Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2alpha formation J. Cardiovasc. Pharmacol. 40 2002 868 874
28. G. Desideri, G. Croce, M. Tucci, G. Passacquale, S. Broccoletti, L. Valeri, A. Santucci, and C. Ferri Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments J. Clin. Endocrinol. Metab. 88 2003 5341 5347
29. A. Kontush, E.C. de Faria, S. Chantepie, and M.J. Chapman A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity Atherosclerosis 182 2005 277 285
30. N.K. Gopaul, E.E. Anggard, A.I. Mallet, D.J. Betteridge, S.P. Wolff, and J. Nourooz-Zadeh Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus FEBS Lett. 368 1995 225 229
31. G. Davi, G. Ciabattoni, A. Consoli, A. Mezzetti, A. Falco, S. Santarone, E. Pennese, E. Vitacolonna, T. Bucciarelli, F. Costantini, F. Capani, and C. Patrono In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation Circulation 99 1999 224 229
32. N. Moussavi, G. Renier, A. Roussin, J.C. Mamputu, J. Buithieu, and O. Serri Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes Diab. Obes. Metab. 6 2004 69 77
33. L. Flores, S. Rodela, J. Abian, J. Claria, and E. Esmatjes F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control Metabolism 53 2004 1118 1120
34. S. Nakanishi, G. Suzuki, Y. Kusunoki, K. Yamane, G. Egusa, and N. Kohno Increasing of oxidative stress from mitochondria in type 2 diabetic patients Diab. Metab. Res. Rev. 20 2004 399 404
35. J.F. Keaney Jr., M.G. Larson, R.S. Vasan, P.W. Wilson, I. Lipinska, D. Corey, J.M. Massaro, P. Sutherland, J.A. Vita, and E.J. Benjamin Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study Arterioscler. Thromb. Vasc. Biol. 23 2003 434 439
36. H. Urakawa, A. Katsuki, Y. Sumida, E.C. Gabazza, S. Murashima, K. Morioka, N. Maruyama, N. Kitagawa, T. Tanaka, Y. Hori, K. Nakatani, Y. Yano, and Y. Adachi Oxidative stress is associated with adiposity and insulin resistance in men J. Clin. Endocrinol. Metab. 88 2003 4673 4676
37. B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M.J. Chapman, and A. Kontush Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity J. Clin. Endocrinol. Metab. 89 2004 4963 4971
38. S. Araki, K. Dobashi, Y. Yamamoto, K. Asayama, and K. Kusuhara Increased plasma isoprostane is associated with visceral fat, high molecular weight adiponectin, and metabolic complications in obese children Eur. J. Pediatr. 169 2010 965 970
39. P. Minuz, P. Patrignani, S. Gaino, M. Degan, L. Menapace, R. Tommasoli, F. Seta, M.L. Capone, S. Tacconelli, S. Palatresi, C. Bencini, C. Del Vecchio, G. Mansueto, E. Arosio, C.L. Santonastaso, A. Lechi, A. Morganti, and C. Patrono Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease Circulation 106 2002 2800 2805
40. L. Zhou, W. Xiang, J. Potts, M. Floyd, C. Sharan, H. Yang, J. Ross, A.M. Nyanda, and Z. Guo Reduction in extracellular superoxide dismutase activity in African-American patients with hypertension Free Radic. Biol. Med. 41 2006 1384 1391
41. J.C. Romero, and J.F. Reckelhoff State-of-the-Art lecture: role of angiotensin and oxidative stress in essential hypertension Hypertension 34 1999 943 949
42. J.L. Cracowski, C. Cracowski, G. Bessard, J.L. Pepin, J. Bessard, C. Schwebel, F. Stanke-Labesque, and C. Pison Increased lipid peroxidation in patients with pulmonary hypertension Am. J. Respir. Crit. Care Med. 164 2001 1038 1042
43. D. Ilyasova, A. Ivanova, J.D. Morrow, M. Cesari, and M. Pahor Correlation between two markers of inflammation, serum C-reactive protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease Biomarkers 13 2008 41 51
44. Y. Dohi, H. Takase, K. Sato, and R. Ueda Association among C-reactive protein, oxidative stress, and traditional risk factors in healthy Japanese subjects Int. J. Cardiol. 115 2007 63 66
45. S. Voutilainen, J.D. Morrow, L.J. Roberts II, G. Alfthan, H. Alho, K. Nyyssonen, and J.T. Salonen Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels Arterioscler. Thromb. Vasc. Biol. 19 1999 1263 1266
46. M.I. Frisard, A. Broussard, S.S. Davies, L.J. Roberts II, J. Rood, L. de Jonge, X. Fang, S.M. Jazwinski, W.A. Deutsch, and E. Ravussin Aging, resting metabolic rate, and oxidative damage: results from the Louisiana Healthy Aging Study J. Gerontol. Biol. Sci. Med. Sci. 62 2007 752 759
47. S.S. Davies, T. Traustadottir, A.A. Stock, F. Ye, Y. Shyr, S.M. Harman, and L.J. Roberts II Ischemia/reperfusion unveils impaired capacity of older adults to restrain oxidative insult Free Radic. Biol. Med. 47 2009 1014 1018
48. M. Gross, M. Steffes, D.R. Jacobs Jr., X. Yu, L. Lewis, C.E. Lewis, and C.M. Loria Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study Clin. Chem. 51 2005 125 131
49. E. Schwedhelm, A. Bartling, H. Lenzen, D. Tsikas, R. Maas, J. Brummer, F.-M. Gutzki, J. Berger, J.C. Frolich, and R.H. Boger Urinary 8-iso-prostaglandin F2{alpha} as a risk marker in patients with coronary heart disease: a matched case-control study Circulation 109 2004 843 848
50. M.H. Shishehbor, R. Zhang, H. Medina, M.-L. Brennan, D.M. Brennan, S.G. Ellis, E.J. Topol, and S.L. Hazen Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease Free Radic. Biol. Med. 41 2006 1678 1683
51. J.Y. Kim, Y.J. Hyun, Y. Jang, B.K. Lee, J.S. Chae, S.E. Kim, H.Y. Yeo, T.-S. Jeong, D.W. Jeon, and J.H. Lee Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study Am. J. Clin. Nutr. 88 2008 630 637
52. J. Ruef, W. März, and B.R. Winkelmann Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease Scand. Cardiovasc. J. 40 2006 274 279
53. M. Woodward, K.D. Croft, T.A. Mori, H. Headlam, X.S. Wang, C. Suarna, M.J. Raftery, S.W. MacMahon, and R. Stocker Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population Clin. Sci. 116 2009 53 60
54. C. Vassalle, L. Petrozzi, N. Botto, M.G. Andreassi, and G.C. Zucchelli Oxidative stress and its association with coronary artery disease and different atherogenic risk factors J. Int. Med. 256 2004 308 315
55. B. Wang, J. Pan, L. Wang, H. Zhu, R. Yu, and Y. Zou Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease Atherosclerosis 184 2006 425 430
56. R.M. LeLeiko, C.S. Vaccari, S. Sola, N. Merchant, S.H. Nagamia, M. Thoenes, and B.V. Khan Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome Am. J. Cardiol. 104 2009 638 643
57. A. Nishibe, Y. Kijima, M. Fukunaga, N. Nishiwaki, T. Sakai, Y. Nakagawa, T. Hata. Increased isoprostane content in coronary plaques obtained from vulnerable patients. Prostaglandins Leukot. Essent. Fatty Acids 78:257-263; 2008.
58. R. De Caterina, F. Cipollone, F.P. Filardo, M. Zimarino, W. Bernini, G. Lazzerini, T. Bucciarelli, A. Falco, P. Marchesani, R. Muraro, A. Mezzetti, and G. Ciabattoni Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E Circulation 106 2002 2543 2549
59. N. Viviana, P. Christian, S. María Pilar, C. Mario, L. Marcelo, L. Sergio, and P. Juan Carlos (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl- coenzyme A and response to atorvastatin in coronary artery disease patients Basic Clin. Pharmacol. Toxicol. 104 2009 211 215
60. N. Kishimoto, T. Hayashi, I. Sakuma, H. Kano-Hayashi, T. Tsunekawa, M. Osawa, K. Ina, and A. Iguchi A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis Int. J. Cardiol. 145 2010 21 26
61. H. Pilz, A. Oguogho, F. Chehne, G. Lupattelli, B. Palumbo, and H. Sinzinger Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane) Thromb. Res. 99 2000 209 221
62. F. Chehne, A. Oguogho, G. Lupattelli, B. Palumbo, and H. Sinzinger Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis Prostaglandins Leukot. Essent. Fatty Acids 67 2002 333 339
63. S. Wassmann, S. Hilgers, U. Laufs, M. Bohm, and G. Nickenig Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction Arterioscler. Thromb. Vasc. Biol. 22 2002 1208 1212
64. G. Davi, M.T. Guagnano, G. Ciabattoni, S. Basili, A. Falco, M. Marinopiccoli, M. Nutini, S. Sensi, and C. Patrono Platelet activation in obese women: role of inflammation and oxidant stress JAMA 288 2002 2008 2014
65. T.J. Montine, M.D. Neely, J.F. Quinn, M.F. Beal, W.R. Markesbery, L.J. Roberts, and J.D. Morrow Lipid peroxidation in aging brain and Alzheimers disease Free Radic. Biol. Med. 33 2002 620 626
66. M. Bougoulia, A. Triantos, and G. Koliakos Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women Horm. (Athens) 5 2006 259 269
67. J.B. Johnson, W. Summer, R.G. Cutler, B. Martin, D.H. Hyun, V.D. Dixit, M. Pearson, M. Nassar, R. Telljohann, S. Maudsley, O. Carlson, S. John, D.R. Laub, and M.P. Mattson Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma Free Radic. Biol. Med. 42 2007 665 674
68. A.B. Crujeiras, D. Parra, I. Abete, and J.A. Martinez A hypocaloric diet enriched in legumes specifically mitigates lipid peroxidation in obese subjects Free Radic. Res. 41 2007 498 506
69. A. Elizondo, J. Araya, R. Rodrigo, C. Signorini, C. Sgherri, M. Comporti, J. Poniachik, and L.A. Videla Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease Biol. Res. 41 2008 59 68
70. E.B. Rimm, M.J. Stampfer, A. Ascherio, E. Giovannucci, G.A. Colditz, and W.C. Willett Vitamin E consumption and the risk of coronary heart disease in men N. Engl. J. Med. 328 1993 1450 1456
71. M.J. Stampfer, C.H. Hennekens, J.E. Manson, G.A. Colditz, B. Rosner, and W.C. Willett Vitamin E consumption and the risk of coronary disease in women N. Engl. J. Med. 328 1993 1444 1449
72. R.S. Crawford, E.A. Kirk, M.E. Rosenfeld, R.C. LeBoeuf, and A. Chait Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse Arterioscler. Thromb. Vasc. Biol. 18 1998 1506 1513
73. D. Pratico, R.K. Tangirala, D.J. Rader, J. Rokach, and G.A. FitzGerald Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice Nat. Med. 4 1998 1189 1192
74. S.R. Thomas, S.B. Leichtweis, K. Pettersson, K.D. Croft, T.A. Mori, A.J. Brown, and R. Stocker Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice Arterioscler. Thromb. Vasc. Biol. 21 2001 585 593
75. M.C. Peluzio, A.P. Homem, G.C. Cesar, G.S. Azevedo, R. Amorim, D.C. Cara, H. Saliba, E.C. Vieira, R.E. Arantes, and J. Alvarez-Leite Influences of alpha-tocopherol on cholesterol metabolism and fatty streak development in apolipoprotein E-deficient mice fed an atherogenic diet Braz. J. Med. Biol. Res. 34 2001 1539 1545
76. T. Cyrus, Y. Yao, J. Rokach, L.X. Tang, and D. Pratico Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions Circulation 107 2003 521 523
77. P. Otero, B. Bonet, E. Herrera, and A. Rabano Development of atherosclerosis in the diabetic BALB/c mice: prevention with vitamin E administration Atherosclerosis 182 2005 259 265
78. J. Virtamo, J.M. Rapola, S. Ripatti, O.P. Heinonen, P.R. Taylor, D. Albanes, and J.K. Huttunen Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease Arch. Intern. Med. 158 1998 668 675
79. J.M. Rapola, J. Virtamo, S. Ripatti, J.K. Huttunen, D. Albanes, P.R. Taylor, and O.P. Heinonen Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction Lancet 349 1997 1715 1720
80. G. de Gaetano Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project Lancet 357 2001 89 95
81. E. Lonn, S. Yusuf, V. Dzavik, C. Doris, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, W. Riley, and K. Teo Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE) Circulation 103 2001 919 925
82. E. Lonn, J. Bosch, S. Yusuf, P. Sheridan, J. Pogue, J.M. Arnold, C. Ross, A. Arnold, P. Sleight, J. Probstfield, and G.R. Dagenais Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial JAMA 293 2005 1338 1347
83. N.G. Stephens, A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseman, and M.J. Mitchinson Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 347 1996 781 786
84. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 23 33
85. D.P. Vivekananthan, M.S. Penn, S.K. Sapp, A. Hsu, and E.J. Topol Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials Lancet 361 2003 2017 2023
86. L.J. Roberts II, J.A. Oates, M.F. Linton, S. Fazio, B.P. Meador, M.D. Gross, Y. Shyr, and J.D. Morrow The relationship between dose of vitamin E and suppression of oxidative stress in humans Free Radic. Biol. Med. 43 2007 1388 1393
87. M. Aviram, L. Dornfeld, M. Rosenblat, N. Volkova, M. Kaplan, R. Coleman, T. Hayek, D. Presser, and B. Fuhrman Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice Am. J. Clin. Nutr. 71 2000 1062 1076
88. M. Aviram, and L. Dornfeld Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure Atherosclerosis 158 2001 195 198
89. M. Aviram, M. Rosenblat, D. Gaitini, S. Nitecki, A. Hoffman, L. Dornfeld, N. Volkova, D. Presser, J. Attias, H. Liker, and T. Hayek Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation Clin. Nutr. 23 2004 423 433